OBJECTIVE: There has been increasing interest in surveillance and ablative techniques for small renal masses (SRM), given the increasing number being diagnosed at smaller sizes. Of the currently available ablative techniques, radiofrequency ablation and cryoablation have been the popular ones. We describe our intermediate-term outcomes with using cryoablation for SRM in patients who were not ideal candidates for partial nephrectomy. MATERIALS AND METHODS: Nineteen patients treated with cryoablation were included. Patients with renal lesions <4 cm were considered for cryoablation, and all patients were treated between 2002 and 2007. Access was either laparoscopic (transperitoneal) or via open surgical techniques. From 2002 to 2004, the CryoCare System (Endocare, Inc., Irvine, CA) was used, with probe sizes ranging from 3 to 5 mm. Before 2004, the SeedNet system (Galil Medical, Arden Hills, MN) was used, with 17-gauge (1.47 mm) IceRod cryoneedles. Recurrence-free survival (RFS) and overall survival (OS) were calculated using Kaplan Meier methodology. RESULTS: The mean age was 56.7 years. The mean tumour size was 2.6 cm (range 1.2-4.0 cm). There were no intraoperative or postoperative complications in the 19 patients. One patient has been lost to follow-up; mean follow up was 41.6 months (range 7-84 months) in the cohort. Recurrence, defined as either increase in size of lesion or enhancement on follow-up imaging, was seen in 4 patients. There was 1 non-cancer specific death, and 1 cancer specific death. CONCLUSIONS: The 4-year RFS rate and OS rate were 83.6% and 94.1%, respectively, in patients with SRM who were unsuitable for partial nephrectomy.
OBJECTIVE: There has been increasing interest in surveillance and ablative techniques for small renal masses (SRM), given the increasing number being diagnosed at smaller sizes. Of the currently available ablative techniques, radiofrequency ablation and cryoablation have been the popular ones. We describe our intermediate-term outcomes with using cryoablation for SRM in patients who were not ideal candidates for partial nephrectomy. MATERIALS AND METHODS: Nineteen patients treated with cryoablation were included. Patients with renal lesions <4 cm were considered for cryoablation, and all patients were treated between 2002 and 2007. Access was either laparoscopic (transperitoneal) or via open surgical techniques. From 2002 to 2004, the CryoCare System (Endocare, Inc., Irvine, CA) was used, with probe sizes ranging from 3 to 5 mm. Before 2004, the SeedNet system (Galil Medical, Arden Hills, MN) was used, with 17-gauge (1.47 mm) IceRod cryoneedles. Recurrence-free survival (RFS) and overall survival (OS) were calculated using Kaplan Meier methodology. RESULTS: The mean age was 56.7 years. The mean tumour size was 2.6 cm (range 1.2-4.0 cm). There were no intraoperative or postoperative complications in the 19 patients. One patient has been lost to follow-up; mean follow up was 41.6 months (range 7-84 months) in the cohort. Recurrence, defined as either increase in size of lesion or enhancement on follow-up imaging, was seen in 4 patients. There was 1 non-cancer specific death, and 1 cancer specific death. CONCLUSIONS: The 4-year RFS rate and OS rate were 83.6% and 94.1%, respectively, in patients with SRM who were unsuitable for partial nephrectomy.
Authors: Paul L Crispen; Stephen A Boorjian; Christine M Lohse; Thomas S Sebo; John C Cheville; Michael L Blute; Bradley C Leibovich Journal: J Urol Date: 2008-09-17 Impact factor: 7.450
Authors: J Louis Hinshaw; Anthony M Shadid; Stephen Y Nakada; Sean P Hedican; Thomas C Winter; Fred T Lee Journal: AJR Am J Roentgenol Date: 2008-10 Impact factor: 3.959
Authors: Khalid Badwan; Keegan Maxwell; Ramakrishna Venkatesh; Robert S Figenshau; Dan Brown; Cathy Chen; Sam B Bhayani Journal: J Endourol Date: 2008-06 Impact factor: 2.942
Authors: Thomas D Atwell; Michael A Farrell; Bradley C Leibovich; Matthew R Callstrom; George K Chow; Michael L Blute; J William Charboneau Journal: J Urol Date: 2008-06 Impact factor: 7.450
Authors: Gladwin C Hui; Kemal Tuncali; Servet Tatli; Paul R Morrison; Stuart G Silverman Journal: J Vasc Interv Radiol Date: 2008-07-21 Impact factor: 3.464
Authors: David S Finley; Shawn Beck; Geoffrey Box; William Chu; Leslie Deane; Duane J Vajgrt; Elspeth M McDougall; Ralph V Clayman Journal: J Urol Date: 2008-06-11 Impact factor: 7.450
Authors: M Pilar Laguna; Patricia Beemster; Vivenkanandar Kumar; Patricia Kumar; H Christoph Klingler; Stephen Wyler; Chris Anderson; Francis X Keeley; Alexander Bachmann; Jorge Rioja; Charalampos Mamoulakis; Michael Marberger; Jean J de la Rosette Journal: Eur Urol Date: 2009-05-13 Impact factor: 20.096